IDO1 Inhibitor PF-06840003

Drug Overview

IDO1 Inhibitor PF-06840003, also known by its co-development name EOS200271, is an investigational oral Immunotherapy agent co-developed by Pfizer and iTeos Therapeutics. It is designed to neutralize one of the most powerful immune-evasion tools that cancer cells use — an enzyme called IDO1 — which allows tumors to chemically suppress the immune system and hide from the body’s own defenses.

PF-06840003 was designed to exhibit good pharmacokinetic properties, a longer half-life potentially allowing for single daily dosing, and CNS penetration for possible use against brain metastases. This brain-penetrating capability made it particularly relevant to glioblastoma — one of the most lethal and treatment-resistant brain cancers known to medicine.

• Name: IDO1 Inhibitor PF-06840003 (also known as EOS200271)
• US Brand Name: None assigned — currently investigational
• Drug Class: Selective IDO1 (Indoleamine 2,3-Dioxygenase 1) Inhibitor / Immunotherapy
• Route of Administration: Oral (tablet, taken by mouth)
• FDA Approval Status: Not FDA-approved. A phase I study evaluated PF-06840003 as monotherapy in patients with recurrent malignant glioma but was prematurely terminated by the sponsor, and no further development for glioma was pursued. Research into IDO1 inhibition in CNS malignancies continues through combination strategies.

What Is It and How Does It Work? (Mechanism of Action)

To understand PF-06840003, it helps to know how glioblastoma and other cancers hide from immune attack. IDO1 is induced in response to inflammatory stimuli such as IFNγ and promotes immune tolerance by depleting tryptophan and producing tryptophan catabolites, including kynurenine, in the tumor microenvironment. This leads to effector T-cell anergy and enhanced Treg function through upregulation of FoxP3.

In plain terms: the tumor uses IDO1 to drain the immune environment of tryptophan — an amino acid that T-cells need to survive and fight — while flooding it with kynurenine, a toxic byproduct that further paralyzes immune cells. PF-06840003 dismantles this chemical shield through three steps:

Novel Non-Heme Binding: PF-06840003 is a representative non-heme-binding IDO1 inhibitor with high selectivity and excellent pharmacokinetics. It inhibits IDO1 without coordinating to the heme iron atom, but with a novel binding mode. This structural distinction means PF-06840003 bypasses resistance mechanisms that affect heme-binding IDO1 inhibitors, giving it a more durable inhibitory effect.

Tryptophan Restoration: With IDO1 blocked, the tumor microenvironment’s tryptophan levels rise. T-cells regain the fuel they need to remain active, proliferate, and mount a direct cancer-killing response inside the tumor.

Collapsing the Kynurenine Shield: In mice carrying syngeneic tumor grafts, PF-06840003 reduced intratumoral kynurenine levels by over 80% and inhibited tumor growth both in monotherapy and, with increased efficacy, in combination with antibodies blocking the immune checkpoint ligand PD-L1. Additionally, anti-PD-L1 therapy results in increased IDO1 metabolic activity, providing additional mechanistic rationale for combining PD-(L)1 blockade with IDO1 inhibition in cancer immunotherapies.

FDA Approved Clinical Indications

Oncological Uses (Under Clinical Investigation — Not FDA-Approved):

• Recurrent malignant glioma including glioblastoma multiforme (GBM) — the primary and most advanced investigated indication (NCT02764151)
• Advanced solid tumors — broader immunotherapy applications under preclinical and early clinical evaluation in combination with checkpoint inhibitors

Non-Oncological Uses:

• There are currently no non-oncological indications under investigation for PF-06840003.

Dosage and Administration Protocols

Sequential cohorts received pre-specified doses of PF-06840003 at 125 mg and 250 mg once daily, followed by 250 mg, 500 mg, 750 mg, and 1000 mg twice daily. Dose escalation followed a modified Toxicity Probability Interval method, targeting a DLT rate of 27.5%.

Clinical Efficacy and Research Results

PF-06840003’s clinical evidence comes from its first-in-human phase I glioma trial (NCT02764151), published in Investigational New Drugs in 2020.

Patients (N=17) received oral PF-06840003 in four dose-escalation groups: 125 mg QD (n=2); 250 mg QD (n=4); 250 mg BID (n=3); 500 mg BID (n=8). Four patients experienced serious adverse events; one with treatment-related SAEs (grade 4 alanine and aspartate aminotransferase elevations). The DLT rate at 500 mg BID was 12.5%; the MTD was not reached.

The pharmacodynamic data confirmed genuine target engagement in the brain — a critical milestone for any CNS-targeted drug. At 500 mg BID, maximum mean percentage inhibition of kynurenine was 75%. PF-06840002 CSF-to-plasma ratio was 1.00, confirming CNS penetration. Disease control occurred in eight patients (47%). Mean duration of stable disease was 32.1 weeks (12.1–72.3 weeks). Two patients with stable disease discontinued the study at 450 and 561 days and continued PF-06840003 on compassionate use.

Although PF-06840003 was well tolerated with pharmacodynamic effect and clinical benefit in the glioma patients enrolled in this trial, the data were limited by the small sample size, nonrandomized design, and low ORR. Further large-scale randomized clinical studies are still needed to support PF-06840003 development.

Safety Profile and Side Effects

Black Box Warning: There is no FDA Black Box Warning for PF-06840003, as it is not FDA-approved. The phase I program established a generally manageable safety profile across all dose levels studied.

Common Side Effects (>10%):

• Fatigue — most frequently reported across dose levels; generally grade 1–2 and does not require dose modification
• Nausea — mild and transient; managed with standard antiemetics
• Headache — consistent with CNS-penetrating agents and the underlying glioma disease burden

Serious Adverse Events:

• Grade 4 Hepatotoxicity (Transaminase Elevation): Serious AEs were observed in 4 patients, one of which was a treatment-related AE. The DLT rate was 12.5% at the highest dose. One patient experienced grade 4 ALT and AST elevations, which resolved with treatment interruption
• Immune-Mediated Reactions: As with all IDO1 immunotherapy agents, immune reactivation may trigger colitis, hepatitis, or endocrinopathy; monitor throughout therapy
• Embryo-Fetal Toxicity: Theoretical risk based on immune pathway modulation; contraception is required during treatment

Management Strategies:

• For grade 3/4 transaminase elevation: hold PF-06840003 immediately; monitor LFTs every 48–72 hours; resume only after full resolution with confirmed dose reduction
• For immune-mediated adverse events: initiate systemic corticosteroids promptly; do not delay for biopsy confirmation in grade 3 presentations
• For fatigue: rule out underlying anemia, infection, or disease progression before attributing to drug

Research Areas

PF-06840003’s development trajectory has directly shaped the broader field of IDO1 inhibitor research in CNS malignancies. Preclinical studies published in Clinical Cancer Research demonstrated that simultaneous administration of an IDO1 inhibitor with radiation and PD-1 blockade provided durable tumor control in 30–40% of mice with advanced intracranial GBM — long-term absence of tumor persisted for ≥150 days of post-treatment monitoring. These findings form the scientific basis for ongoing next-generation trials combining IDO1 inhibition, checkpoint blockade, and radiotherapy in GBM. IDO1 is rapidly stimulated and highly expressed in glioblastoma in response to ongoing immune surveillance, with increased levels of intratumoral IDO expression directly associated with worse overall survival in GBM patients — confirming this pathway as a critical and ongoing research priority.

Patient Management and Practical Recommendations

Pre-Treatment Tests:

• Liver function tests (LFTs) including ALT, AST, and bilirubin — mandatory baseline
• Complete blood count (CBC) with differential
• MRI brain with contrast — baseline tumor burden and CNS status assessment
• IDO1 expression profiling where available — may serve as a predictive biomarker
• Pregnancy test for all women of childbearing age

Precautions During Treatment:

• Monitor LFTs before each dose escalation step and at regular intervals throughout treatment
• Report any new or worsening neurological symptoms immediately — distinguish drug effect from tumor progression
• PF-06840003 is available only through participation in an approved clinical trial

Do’s and Don’ts:

• DO take PF-06840003 at the same time each day to maintain consistent drug levels
• DO report any fever, unusual fatigue, or yellowing of the skin or eyes immediately
• DO attend all scheduled pharmacokinetic blood sampling and MRI imaging appointments
• DON’T take PF-06840003 outside of a supervised clinical trial — it is not available for routine use
• DON’T become pregnant during treatment — immune pathway modulation carries theoretical fetal risk
• DON’T self-manage any side effects without consulting your oncology team first

Legal Disclaimer

The information in this guide is for educational purposes only and does not constitute medical advice, diagnosis, or a treatment recommendation. IDO1 Inhibitor PF-06840003 is an investigational drug that is not approved by the US Food and Drug Administration (FDA) or any major regulatory authority for routine clinical use. It is currently available only through participation in approved clinical trials. All treatment decisions must be made in consultation with a qualified oncologist or licensed healthcare professional with full knowledge of the patient’s complete medical history. This content does not replace official investigational protocol documentation or professional medical judgment.